HSK41959
/ Haisco
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
May 13, 2025
Phase I Study of HSK41959 in Solid Tumors With MTAP Deletion
(clinicaltrials.gov)
- P1 | N=245 | Recruiting | Sponsor: Haisco Pharmaceutical Group Co., Ltd.
New P1 trial • Solid Tumor
March 06, 2024
HSK41959-2: An oral MTA-cooperative PRMT5 inhibitor for MTAP deleted cancer
(AACR 2024)
- "Meanwhile in the HCT116 MTAP-WT xenograft model, HSK41959-2 did not show tumor growth inhibition at 100 mpk. In conclusion, HSK41959-2 is a promising oral MTA-cooperative PRMT5 inhibitor, it was nominated as a development candidate."
Oncology • CD34 • MTAP
1 to 2
Of
2
Go to page
1